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Marine bioprospecting is the systematic search for and discovery of products from Nature, 
with potential of being developed into commercially available pharmaceuticals. The ocean 
represents the largest habitat on Earth, and represent a great resource of organisms with 
unique biological and chemical diversity. The marine environment makes the living condition 
challenging. To survive these conditions, marine organisms produce numerous potent 
secondary metabolites to avoid predation and invasion by pathogenic microorganisms. Due 
to their natural function and chemical diversity, secondary metabolites are believed to have 
enormous potential as lead compounds in development of commercial products. 
 
The aim of this thesis was to isolate and characterize halogenated secondary metabolites from 
organic extracts of Arctic marine Hydroids. The crude organic extracts were analyzed by using 
UHPLC-HR-MS, to evaluate the presence of known and already reported compounds. Based 
on the data from the HR-MS analysis, three brominated compounds believed to be novel were 
selected for isolation. Chemistry-guided isolation was conducted for the selected compounds 
using mass guided preparative HPLC. During the isolation process, two other compounds were 
selected for isolation for the reason that they appeared to be present in abundant amount 
and that seems easy to isolate, in addition to the preselected compounds. At the end, one 
compound was isolated in amounts allowing structure elucidation using NMR, and turned out 
to be the known compound Loliolide. Loliolide was first isolated from Lolium perenne in 1964, 
but this is the first time that this compound has been isolated from Hydroids. The compound 
was screened for antibacterial activity and inhibition of biofilm formation, but no bioactivity 
was found. The result form this thesis shows that isolation of a high enough amount of 
secondary metabolites for structure elucidation and bioactivity screening can be a challenge 
due to difficulty of collecting enough biomass. The results also shows that previously reported 
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1D  One-dimensional 
2D  Two-dimensional 
ACN  Acetonitrile 
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COSY  Correlation spectroscopy 
DMSO  Dimethyl Sulfoxide 
ESI  Electrospray ionization 
h  hour 
HMBC  Heteronuclear multiple-bond correlation 
HSQC  Heteronuclear single quantum coherence 
HPLC  High performance liquid chromatography 
HR-MS  High-resolution mass spectrometry 
MeOH  Methanol 
MS  Mass spectrometry 
NMNP  New marine natural product 
NMR  Nuclear magnetic resonance 
NP  Natural product 
Q  Quadrupole 
ROESY  Rotating frame nuclear overhauser effect spectroscopy 
Rf  Radio frequency 
ToF  Time of Flight 
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1.1 Marine bioprospecting 
 
Marine bioprospecting, is the systematic search for interesting and unique genes, 
biomolecules or designs from the marine environment. The definition is broad, and the scope 
of the definition is not conclusive (1). In this thesis however, the term marine bioprospecting 
is used to describe the search for small molecules in organic extracts of Arctic marine hydroids, 
with potential of being developed into commercially available pharmaceuticals. Marine 
bioprospecting describes the procedure of biomass collection, extraction, compound 
purification, bioactivity screening and structure determination of compounds from marine 
organisms (2). This is followed by bioactivity profiling of the compounds. The ocean represents 
the largest habitat on Earth, and covers more than 70 % of Earth´s surface. This represent a 
great resource of organisms with unique biological and chemical diversity. The Arctic marine 
environment makes the living condition challenging. The seasonal changes in light condition, 
from complete darkness during winter to 24 h sunlight during summer, and the cold waters 
makes the ability to adapt critical to survive. To survive these challenging condition, and to 
avoid predation and invasion by pathogenic microorganisms, the marine organisms produce 
numerous secondary metabolites (3).  
 
Collection of marine invertebrates has until now been the most important source of new 
marine natural products (NMNPs). Marine invertebrates does not have an adaptive immune 
system, but rather a chemical defense system, and therefor produces potent natural products 
(NPs) to protect themselves in a hostile environment (4). These NPs have been shown to 
exhibit pharmacological activities such as anti-inflammatory, anti-diabetes and anti-cancer 
activity to mention a few (5). Increasing evidence shows that natural products (NPs) isolated 
from invertebrates frequently are produced by symbiotic microorganisms, such as bacteria or 
cyanobacteria (6). As an example, Yondelis®, an anti-cancer agent approved in 2007 in Europe 
for soft tissue sarcoma, was first isolated from the marine tunicate Ecteinascidia turbinata, 
which is a Caribbean Sea squirt. It was later strongly suggested that this compound was in fact 




frumentensis (6, 7). Many microorganisms are host specific and they have been proven 
difficult to grow in culture (8, 9). Collection of marine invertebrates is therefor still important 
for the discovery of NMNPs in the future.  
 
Marine organisms often produce halogenated secondary metabolites, with bromine being the 
most commonly incorporated halogen, due to the relative high bromine concentration in sea 
water. This is contrary to terrestrial organisms which often produce chlorinated compounds 
(10). Other halogen containing compounds are quite rare, but fluorinated an iodinated 
compounds are reported. From 1968 there has been discovered more than 5000 halogenated 
natural products and these numbers are steadily increasing. Many of the halogenated natural 
products discovered from marine organisms have reported a large range of biological activity, 
and the activity of many NP’s are influenced by the presence of halogenated substituents (11, 
12). The mechanisms of incorporating halogens to NP’s is complex, and their biosynthesis have 
been studied for over 40 years. Nature has adopted a wide variety of chemistries to optimize 
the bioactivity of natural products by incorporation of halogens to secondary metabolites. 
Enzymatic halogenation through oxidative mechanisms is the most common path of 
producing halogenated metabolites. Halogenation via halide anion incorporation through 
both enzymatic and non-enzymatic pathway is also known (13, 14). 
 
1.1.1 The marine bioprospecting pipeline 
There are several ways of conducting bioprospecting. Most often, several techniques are 
employed in sequence. At Marbio, samples are first collected, either by bottom scraping or 
SCUBA diving. The aim is to collect biomass in amounts sufficient for compound isolation, 




At Marbio all samples are by routine extracted by dicing and freeze-drying the collected 
biomass. The dry biomass is ground and subjected to an aqueous extraction by adding water 
for 24 h. The mixture is centrifuged and the supernatant and pellet are separated. The 
supernatant is dried and with this becomes the aqueous extract. In addition to containing the 




freeze-dried and added a 50:50 mixture of methanol (MeOH) and dichloromethane (DCM) and 
left for 24 h. The mixture is then filtered and the filtrate is dried under reduced pressure, 
resulting in the organic extract.   
 
 Flash fractionation 
 
The crude extracts are pre-fractionated using flash chromatography, using a column packed 
with Diaion HP20SS packing material. To prepare the sample, aliquots of the organic and 
aqueous extracts (approximately 2 g) are dissolved in hexane and mixed with 1 g column 
material, before the mixture is dried under reduced pressure. This allows the sample 
components to form strong interactions with the packing material. The mixture is applied to 
the top of a prepacked column and the mobile phase is flushed through the column. The 
mobile phase composition is changed in a step-wise manner, starting with 5 % MeOH and 
ending with 100 % acetone. The first fractions contain the most water-soluble substances and 
the later fractions contain the most lipophilic substances. All of the fractions are then dried 
under vacuum and redissolved in dimethyl sulfoxide and stored at -23 °C in the dark until 
primary activity screening is conducted.  
 
 Primary activity screening 
 
The finished fractions are submitted to a primary bioactivity screening. The bioassays can be 
divided into two groups: target-based assays and phenotypic assays. Target-based assays 
conducted at Marbio is kinase and anti-diabetes assays. Phenotypic assays used at Marbio are 
cell-based assays and include anticancer, antibacterial, antioxidant and immunostimulatory 
and immunosuppression assays (15). The results from this primary screening  will normally be 
the basis for the bioactivity guided isolation routinely conducted at Marbio. 
 
 The bioprospecting pipeline conducted as part of this thesis 
 
As part of this thesis, chemistry-guided isolation was conducted. This isolation strategy share 
some common approaches as bioassay-guided isolation, but the pre-fractionation and 




analyzed using Ultra-high Performance Liquid Chromatography-High Resolution Mass 
Spectrometry (UHPLC-HR-MS) to identify known an already reported compounds in the 
extracts (dereplication). This process reduces the risk of isolating compounds previously 
identified and described in the literature. By using HR-MS, the elemental composition of a 
compound is statistically calculated from its accurate mass and isotopic pattern. The obtained 
data can be used to search in online databases like MarinLit, Marine Natural Product Database 
and Chemspider for comparison of the data with available compound information. The 
isolation was initiated based on defined chemical properties of the compounds, and here a 
compound was determined to be interesting based on its solubility and elemental 
composition. Halogenated compounds are easy to identify due to their characteristic isotope 
pattern, and in this work brominated compounds were selected as target compounds. Novel 
compounds or known compounds with potential novel bioactivity were selected for isolation, 











1.1.2 Natural products: primary- and secondary metabolites 
Natural products (NP) refer to any compounds produced by living organisms: animals, plants 
and microorganisms (17).  
 
Primary metabolites 
All living organisms biosynthesis organic compounds that are crucial for normal growth, 
development, reproduction and structure, hence the term primary metabolites. These 
metabolites are critical for the immediate survival of the producing organism, and include 
carbohydrates, proteins, fats, amino acids and nucleic acids (18). 
 
Secondary metabolites 
Other natural products are distributed much more limited in nature. These products are not 
needed for the immediate survival, growth and development of the organism and are 
therefore called secondary metabolites. The organism produce these compounds to increase 
their chances of long-term survival, and are often produced to affect interactions between the 
organism itself and the surrounding environment (19). They can act as anti-feeding agents, to 
repel pathogens or biofouling organisms, or to avoid overgrowth by the organisms competing 
for the same space (20, 21). The production of secondary metabolites is often not constant, 
but rather initiated as a response to an external threat (22).  
 
1.1.3 Marine secondary metabolites 
More than 20,000 compounds have been discovered from marine organisms since 1960. 
Weinheimer and Spragginsthe discovered prostaglandins in the Caribbean octocoral Plexaura 
homomalla at the same time as prostaglandins were discovered as an important compound 
in humans, this led to interest in further search for novel compounds from the sea (23).  
 
The total number of drugs of marine origin approved by the U.S. Food and Drug Administration 
is seven, and 22 marine compounds are currently part of the clinical trial pipeline, as of March 
2018 (24). The first FDA approved marine derived drug was the anticancer pyrimidine 
analogue cytarabine (Cytosar-U®) in 1969, isolated from the sponge Cryptotheca crypta (25). 
Following this, three additional marine derived anticancer agents have been approved. These 




pharmaceutical, approved in 2015 (26, 27), the antibody-drug conjugate brentuximab vedotin 
(Adcetris®) and eribulin mesylate (Halaven ®). In addition, omega-3 fatty acid ethyl esters 
(Lovaza ®) are approved to treat hyperglyceridemia, Ziconotide (Prialt ®) to treat severe 
chronic pain and vidarabine (Vidarabine ophthalmic®) to treat optical virus infections are 
approved (28).  
 
1.2 Hydroids from the phylum Cnidaria 
 
Cnidaria is a phylum that contains over 9,000 species, and most of them are found in the 
marine environment. Cnidarians are classified into four main classes; anthozoa, cubozoa, 
scyphozoa and hydrozoan. They have no organs, but they have a gastrovascular cavity which 
act as a mouth and anus. Most are dipoblastic phylum, which means that they are only 
composed of two cell layers, the outer layer is called ectoderm and the inner layer called 
endoderm. All the Cnidarians have explosive stinging or adhesive cells called cnidocytes 
(hence the name Cnidarian) in the tentacles and/or the mouth lining. A cnidocyte contains a 
surface cilium or modified cilium (the cnidocil), and a nematocyst that is the actual stinging 
element. The nematocysts contain toxins that can paralyze and kill prey and then the tentacle 
leads the prey to the mouth (29). Hydrozoa includes nearly 3500 species, but despite this, 
there are only a few of them that have yielded interesting marine natural products (30). This 
is probably because the secondary metabolite content of most hydrozoans has not been 
investigated yet.  
 
Cnidarians have proven to be a fruitful source of NMNP´s, where terpenoids are most 
frequently reported (31). In 2012, breitfussin A and B were isolated from the Arctic hydrozoan 
Thuiaria breitfussi from Bjørnøya, these are  brominated compounds, in addition, breitfussin 
A also contains iodine (32). In 2016, two brominated-indoles were reported from the hydroid 
Abietinaria abietina, which were found to activate NF-kB dependent transcription (33). 
Annulins A, B and C were isolated from the marine hydroid Garveia annulata, and potently 
inhibit indolamine 2,3-dioxygenase, which is thought to play a role in evasion of T-cell-
mediated immune rejection, and Solandelactones C, D, and G isolated from the hydroid 




for novel anticancer agents (30). These are some examples of interesting NPs found in 
hydrozoan. 
 
1.3 High Performance Liquid Chromatography (HPLC) and Ultra-High Performance Liquid 
Chromatography (UHPLC) 
 
HPLC is a commonly used chromatographic technique to separate compounds dissolved in a 
liquid solvent. The LC system is assembled of a mobile phase reservoir, pump, sample injector, 
column and a detector. In liquid chromatography, the mobile phase is liquid, and passes 
through a column that is packed with a stationary sorbent, which can interact and retain 
analytes in the mobile phase. The analytes are injected into the flow of the mobile phase 
before it is forced through the separation column. The column is connected to a detector, 
which detects the substances eluting from the column. 
 
In this thesis, there will be used reverse phase chromatography, where hydrophobic groups 
are chemically bound to silica particles inside the column. In these columns the interaction 
that retains the analytes is mainly based on hydrophobic interactions of Van der Waals forces. 
The mobile phases in reversed phase chromatography are a mixture of water and other water 
miscible organic solvents, where acetonitrile and methanol are most commonly used. 
 
UHPLC is similar to HPLC, the difference is the size and shape improvements of the silica 
particles in the column. The diameter can be below 2 m whereas in HPLC the particle 
diameter is typically 3-10 m. The column is often shorter in UHPLC because of the smaller 
particles. UHPLC utilizes higher pressure (over 10,000 psi compared to about 6,000 psi for 
HPLC), which result in shorter analysis time, and the peak capacity and resolution are 






1.4 Mass Spectrometry 
 
Mass spectrometry is an analytical method where the ions in gas phase are separated 
according to their mass-to-charge ratio (m/z), and detected in the detector. In this project, ESI 
single quadrupole mass separator preparative HPLC was used for isolation of the compounds 
of interest, and ESI-QTOF mass separator for analysis of compounds in the crude extracts. 
 
1.4.1 Electrospray ionization (ESI) 
ESI is an ionization technique among the group of atmospheric pressure ionization (API), and 
is the ionsource used in the mass spectrometers at Marbio. In this ionization technique, the 
mobile phase with the analytes are pressed through a charged stainless steel capillary that 
ionizes molecules in the mobile phase. The mobile phase is sprayed as an aerosol at 
atmospheric pressure and the mobile phases are rapidly evaporated while the charge is 
transferred to analyte molecules. ESI is a soft ionization technique (the molecule is typically 
not broken down into smaller fragments) that transfers ions from a solution, to gas phase at 
atmospheric pressure and then continue into the mass analyser under vacuum (35). 
When an analyte in solution is transferred to gas phase ions, the solution undergoes four 
processes. (a) Electrochemical reactions (oxidation reaction when positive ion mode is used) 
inside the ESI capillary, which produce charge in the solution, (b) Production of charged 
droplets from the high-voltage capillary tip, (c) Solvent evaporation from the charged droplet 
(micro range size) resulting in very small charged droplets (nano range size), (d) and finally the 
mechanism of the formation of gas-phase ions from the very small charged droplet (36). 
 
1.4.2 Quadrupole (Q) 
The quadrupole is made up of four parallel metallic rods, that are applied a constant DC 
voltage to each rod pair, one pair is positive and the other is negative on opposite planes. It is 
also applied an alternating radio frequency (RF) oscillating voltage on each pair of rods. 
Typically, the DC and RF potentials are adjusted in such a way that only molecules with one 






1.4.3 Time of flight (ToF) 
The ions from the ion source is introduced to a mass filter in a vacuum chamber and into the 
time of flight mass analyser. The mass of the compound is measured by the time it takes for 
the compound to reach the detector from the ion pusher. The background pressure must 
therefore be so small that no collision between them happens, to not interfere with the exact 
flight time. The ions that are emitted from the ion pusher, are accelerated so they have equal 
kinetic energy before entering the field free drift region (the flight tube). The kinetic energy 
(E) is equal to ½ mv2, and as the equation shows, ions with smaller masses will have higher 
velocity, and therefor reach the detector first. Velocity (v) is equal to distance (d) divided by 
time (t), so by combining these two equations the mass of a compound can be calculated by 
measuring the flight time (37). 
 
ToF-MS is a high-resolution mass filter, that means that ions with very similar masses can be 
separated, as opposed in e.g. a quadrupole which is a low-resolution mass filter (38). The 
instrument also have a high mass accuracy, which means that it has the ability to measure m/z 
with only a few parts per million errors of the true monoisotopic m/z of a compound (39). The 
combination of high resolution, high mass accuracy and high sensitivity in full scan mode 
makes HR-MS an ideal  instrument to analyse complex samples such as crude extracts from 






1.5 Nuclear magnetic resonance spectroscopy (NMR) 
This technique is mainly used to identify the carbon-hydrogen skeleton of a molecule. Some 
atomic nuclei behave like small magnetics by spinning around it´s own axis, called “nuclear 
spin”. This spin results in small magnetic fields which can be influenced by a fixed external 
magnetic field from a NMR instrument. In organic chemistry both proton (1H) and carbone 
(13C) have the correct spin quantum number (1/2) and can be analysed using NMR. The nuclei 
are randomly oriented, but will be aligned parallel when they are subjected to an external 
magnetic field, aligning either with (+1/2) or against (-1/2) the external field. The nuclei that 
are aligned against the external magnetic field are in the higher-energy spin stat. The sample 
is then applied energy in the radio frequency (rf) range. When a nucleus in the lower-energy 
spin state (aligning with external field) is subjected to a rf frequency identical to the nucleus’ 
Larmour frequency, the nucleus flip to the higher energy spin state, aligning against the 
magnetic field. When the rf is switched off, the nuclei relaxes back to the lower energy state 
by re-emitting the absorbed energy. The emitted energy of a particular resonance frequency 
produces a measurable rf signal, and is processed into a NMR spectrum (41, 42). NMR spectra 
can be either one-dimensional (1D) or two-dimensional (2D). 1D experiments are analyses of 
a single nucleus. In 2D experiments, interactions between different nuclei can be detected. 
The most used 2D-NMR experiments for structure elucidation is correlated spectroscopy 
(COSY), heteronuclear multiple quantum correlation (HMQC), heteronuclear multiple bond 
correlation (HMBC), and nuclear overhauser enhancement spectroscopy (NOESY) (43).  
 
 
Figure 2: Illustration of nuclei aligned either with or against an applied magnetic field. The spine state +1/2 is 
aligned with the field and therefor is of lower energy, while the spin state -1/2 is aligned against the field and 




2 The aim of the thesis 
 
The overall aim of this thesis was to identify and isolate halogenated secondary metabolites 
from Arctic marine hydroids, and conduct bioactivity profiling of the compounds isolated using 
bioassays available at Marbio.  
 
The main objectives of the thesis were to: 
 
 Dereplicate the crude extract in order to nominate compounds for isolation based on 
suspected interesting chemistry and novelty of the compound 
 Isolate target compounds from organic extracts of Arctic or Sub-arctic hydroids 
 Elucidate the structure of the isolated compounds 






3 Materials and methods 
 
As part of this thesis, sample of hydroids with low collected sample weight were used as 
biomass. The low collected sample weight resulted in low amount of organic extract, and 
therefore, the normally conducted flash fractionation and primary bioactivity screening steps 
were skipped. Instead, the organic extracts of the hydroids were analysed using high 
resolution mass spectrometry (HR-MS) to identify compounds with interesting chemistry. To 
conclude, the normally conducted strategy to isolate bioactive compounds (bioactivity guided 
isolation) was exchanged for a different approach: chemistry guided isolation. If this strategy 
works, this will show that samples, previously put aside to wait for the collection of additional 
biomass at Marbio, can be analyzed with a different approach to yield interesting compounds. 
 
Table 1 shows the two samples used in this thesis. The M17017 sample contains one specific 
specie, and M17015 sample is a mixture of different species, including the same species as in 
M17017 sample. The M17015 sample was included in this work as it contained all the 
compounds isolated from the M17017 sample, and because of the higher amount of organic 
extract, which provide more amount of the target compounds.  
 














M17015 Mix of different families   
173.77 g 1.1 g 
M17017 LAFOEIDAE GRAMMARIA ABIETINA 




3.1 Extraction of hydroids 
The materials and equipment used during extraction can be seen in Table 2.  
 
Table 2: Materials and Equipment used in the extraction process. 
Materials/Equipment  Supplier 
MilliQ water Millipore, Billerica, MA, USA 
DCM (≥ 99.8 %) Sigma-Aldrich, MO, USA 
MeOH (≥ 99.9 %) Sigma-Aldrich, St.Louis, MO, USA 
Whatman filter paper 125 Ø (no.3) Sigma-Aldrich, MO, USA 
Centrifuge: Heraus Multifuge 3 S-R Hanau, Germany 
Freeze-drier: Heto PowerDry PL9000 and Heto 
PowerDry PL6000 
Thermo Fisher Scientific, Waltman, MA, USA 
Rotary evaporator, Heidolph Laborota Heidolp Instruments GmbH & Co, Germany 
Scale: Mettler Toledo PB3002-S Fact Greifensee, Switzerland 
A11 Basic grinder IKA Works, Staufen, Germany 
 
Extraction of the collected hydroid biomass 
The biomass samples were stored at -22°C in the dark before being extracted. The samples 
were then freeze-dried for 2-3 days, and the freeze-dried samples were pulverized with a 
grinder and transferred to tared 1 L Duran bottles, weighed and stored in the freezer at -22°C.   
 
Aqueous extraction 
The pulverized sample was transferred to 0.6 L centrifuge bottles and added MilliQ water 
approximately ten times the dry weight of the sample and shaken until the suspension got a 
slurry consistency. The suspension was centrifuged at 4565 g, at 5 C for 30 minutes. The 
supernatant was transferred to a Pyrex dish covered with aluminium foil and stored in the 
freezer -22°C. The pellets were re-extracted with MilliQ water, approximately half the amount 
used the first round, and shaken until the suspension got slurry consistency. The suspension 
was stored in the refrigerator at 5 °C for about 30 minutes before it was centrifuged as before. 
The supernatant was transferred to another Pyrex dish as before and stored in the freezer 
over night at -22 °C. The pellets were transferred to a Pyrex dish, covered with aluminium foil 
and stored in freezer over night at -22 °C. The water extracts were frozen at –80 C for 2-3 
hours before freeze-drying for 2-3 days, before grinded with mortar and pestle. The resulting 
powder was termed the aqueous extract, and stored in a 50 mL falcon tube in the freezer at -







The pellets were freeze dried for 2-3 days, grinded in mortar and transferred to a tared 1 L 
Duran bottle. The pellets were then extracted with a solvent mixture of DCM-MeOH (1:1, v/v), 
of approximately ten times the weight of the pellets until the suspension got a slurry 
consistency. The suspension was stored in the refrigerator at 5 °C to the next day, before it 
was vacuum filtered with Whatman filters. The material on the filter was transferred back to 
the bottle and the extraction was repeated one more time with approximately half of the 
solvent volume used in the first extraction. The suspension was shaken and stored for 30 
minutes in refrigerator before it was filtered again. The filtrate was then concentrated to 10-
20 mL on a rotary evaporator before it was transferred to a 50 mL Florence flask and 
evaporated under reducing pressure until the extract was dry, then stored at -22 C. 
 
3.2 Preparation of the samples for MS analysis 
 
Aliquots of organic extract from the M17015 and M17017 samples was transferred to an 
Eppendorf tube and dissolved in 0.5 mL MeOH ( 99.9 %, Sigma-Aldrich, St.Louis, MO, USA). 
The dissolved sample was transferred to HPLC vials for further UHPLC-HR-MS analysis.  
 
3.3 UHPLC-HR-MS analysis (dereplication) 
The materials and equipment used in the dereplication analysis can be seen in Table 3. 
 
Table 3: Materials and equipment used in dereplication of organic extracts employed in UHPLC-HR-MS analysis. 
Materials/Equipment Supplier 
MilliQ water Millipore, Billerica, MA, USA 
MeOH LC-MS Ultra CHROMASOLV® Thermo Fisher Scientific, MA, USA 
LiChrosol® ACN (hypergrade for LC-MS) Merck KGaA, Germany 
Formic Acid ULC/MS (99%) Biosolve B.V., Netherland 
Vion® IMS qTOF Waters, MA, USA 
Acquity I-Class UPLC Waters, MA, USA 
Acquity UPLC® BEH C18, 2.1x100 mm, 1.7µM 
Column 
Waters, MA, USA 
Acquity Sample Manager FTN Waters, MA, USA 
Acquity UPLC® I-Class Binary Solvent Manager Waters, MA, USA 
Acquity UPLC® PDA Detector Waters, MA, USA 






All of the organic extracts of the samples M17015-M17028 (for table, see appendix A1) were 
analysed using UHPLC-HR-MS to look for novel compounds with interesting chemistry. The 
two samples that were used for further preparation and isolation, M17015 and M17017 
contained interesting compounds and were two of the samples with the highest amount of 
extracts. The gradient and instrument parameters used in the analysis are described in table 
4 and 5. 
 
Table 4: Gradient used in UHPLC-HR-MS analysis of the organic extracts. Mobile phase A: ultra-pure water with 
0.1 % formic acid (FA), and mobile phase B: ACN with 0.1 % FA. 
Time (min) Flow (mL/min) A (%) B (%) 
Initial 0.450 90 10 
12.00 0.450 0 100 
13.50 0.450 0 100 
 
 
Table 5: Instrument parameters used in UHPLC-HR-MS analysis. 
Polarity Positive 
Low mass (m/z) 50 
High mass (m/z) 2000 
Source type  ESI 
Source temperature (°C) 120 
Desolvation temperature (°C) 450 
Desolvation gas flow (L/h) 800 
Capillary voltage (kV) 0.80 
Cone voltage (V) 30 







3.4 Preparation of the organic and aqueous extract of sample M17015 and M17017 
The material and equipment used during the extraction of the extract of M17015 and M17017 
sample can be seen in Table 6. 
 
Table 6: Materials and equipment used in the preparation of organic extracts for isolation. 
Materials/Equipment Supplier 
MeOH ( 99.9 %) Sigma-Aldrich, St.Louis, MO, USA 
MilliQ water Millipore, Billerica, MA, USA 
Hexane ( 97.0 %) Sigma-Aldrich, St.Louis, MO, USA 
Rotary evaporator: Heidolph Laborota 4002 Nürnberg, Germany 
Centrifuge: Heraeus Multifuge 3 S-R Hanau, Germany 




The Florence flask containing the extract was weighed four times on an analytic scale to make 
the measurement as exact as possible. The Florence flasks were added 25 mL hexane, which 
then was transferred to a separatory funnel. The process was repeated until the Florence flask 
was clean. The Florence flask was then weighed again to determine the weight of the organic 
extract. The separatory funnel was added a volume of approximately 150 mL hexane and 100 
mL 90% MeOH and shaken. When the two phases separated, the MeOH phase (the lower 
phase) was transferred to a new Florence flask. The shaking and transferring was repeated 
three times into the same Florence flask. The solvent was evaporated on a rotary evaporator 
until the sample was dry. The dry sample was added 4 mL MeOH and spinned on the rotary 
evaporator (without vacuum) to completely redissolve the dried sample, and then transferred 
to a glass tube. Then the Florence flask, containing residues of the prepared organic extract, 
was added 2 mL MeOH multiple times until all of the sample was dissolved, and transferred 
to the tube. The organic phase was stored in the refrigerator at 5 °C until use.  
 
Aqueous extract 
All of the dry aqueous extract was transferred to a tared falcon tube and added 20 mL 90 % 
MeOH, mixed and centrifuged at 4565 g, at 5 C for 2 minutes. The supernatant was 
transferred to a Florence flask after centrifugation, and this process was repeated three times. 
The sample was then evaporated on a rotary evaporator until the sample was dry. The dry 
sample was added 4 mL MeOH, spun down and transferred to a glass tube, as the procedure 





3.5 Scout run HPLC analysis of M17015 and M17017 extracts 
 
Scout means searching/looking for something. In this thesis, the scout run was used to 
determine the optimal isolation and purification conditions. This was achived by injecting a 
definite volume from each samples onto different HPLC columns. Based on the results from 
the different columns, the best column for isolation and purification was selected. The 
materials and equipment used during scout run analysis can be seen in Table 7. 
 
Table 7: Materials and equipment used in scout run analysis and isolation. 
Materials/Equipment Supplier 
ACN (99.8 %) Sigma-Aldrich, St. Louis, MO, USA 
Formic Acid (98.0 %) Sigma-Aldrich, St. Louis, MO, USA 
MeOH ( 99.9 %) Sigma-Aldrich, St.Louis, MO, USA 
MilliQ water Millipore, Billerica, MA, USA 
XSELECT CSH Prep Fluoro-Phenyl, 5 m, 10x250 
mm column 
Waters, MA, USA 
Atlantis Prep C18, 10 m, 10x250 mm column Waters, MA, USA 
XTerra Prep C18, 10 m, 10x300 mm column Waters, MA, USA 
XSELECT CSH Prep Phenyl-Hexyl, 5 m, 10x250 
mm column 
Waters, MA, USA 
 
 
Both the organic and aqueous extracts were analysed using preparative HPLC-MS with the 
instrument parameters and mobile phase gradient described in table 8 and 9, to look for the 
targeted compounds for isolation and further structure elucidation. The samples were 
injected on four different columns with an injection volume of 200 L on each column, to 
determine which column to use for the isolation. When isolating a sample using mass guided 
preparative HPLC, several isolation rounds are needed to completely remove sample 
impurities from the compound of interest. The chromatograms from the scout runs can also 
be used when selecting columns for the second and third rounds of isolation. From the scout 
run chromatograms, the columns were evaluated after which columns separated the 
compounds of interest from the impurities, and also by the chromatography of the compound 







Table 8: Gradient used for the scout run analysis and isolation from the organic extracts. Mobile phase 
A: ultra-pure water with 0.1 % Formic acid (FA), and mobile phase B: ACN with 0.1 % FA. 
Time (min) Flow (mL/min) A (%) B (%) 
Initial 6.00 90 10 
15.00 6.00 0 100 
20.00 6.00 0 100 
20.10 6.00 90 10 




Table 9: Overview of instrument parameters used during scout run and isolation from the organic extracts of 
M17015 and M17017 samples with prep-HPLC. 
Source Temperature C 120  
Desolvation Temperature  C 300  
Desolvation Gas Flow (L/h) 650 
Polarity ES+ 
Low mass (m/z) 200 
High mass (m/z) 1000 
Source type ESI 
 
 
3.6 Isolation of target compounds from the organic extract of M17015 and M17017 using prep 
HPLC-MS 
 
The material and equipment used during isolation of the target compounds from the organic 
extract of M17015 and M17017 are listed under the method “3.5 scout run HPLC analysis of 
M17015 and M17017 extracts”. The instrument parameters and mobile phase gradient used 
for isolation can be seen in Table 8 and 9.  
 
The compounds isolated from the organic extract of M17017 were isolated and purified using 
two rounds of HPLC separation (Table 10). Compounds isolated from the organic extract of 







Table 10: All isolated compounds from the extract of M17017 according to the different columns used for the 
first and second isolation run. The gradient used for each isolation is illustrated in table 8.  
Compound  HPLC separation round Column 
2 First Fluoro-Phenyl 
Second Phenyl-Hexyl 
3 First Fluoro-Phenyl 
 Second Phenyl-Hexyl 
4 First Fluoro-Phenyl 
Second Xterra C18 
5 First Fluoro-Phenyl 
Second Xterra C18 
 
 
Table 11: All isolated compounds from the extract of M17015 according to the different column used for the 
first, second and third isolation run. The gradient used for each isolation is illustrated in table 8.  
Compound  HPLC separation round Column 
1 First Atlantis C18 
Second Xterra C18 
2 First Atlantis C18 
Second Xterra C18 
Third Phenyl-Hexyl 
3 First Atlantis C18 
 Second Xterra C18 
 Third Phenyl-Hexyl 
4 First Atlantis C18 
Second Xterra C18 
Third Xterra C18 
5 First Atlantis C18 
Second Xterra C18 








3.7 NMR analysis of isolated compounds from the organic extracts M17015 and M17017 
Johan Isaksson at the Department of Chemistry at UiT The Arctic University of Norway 
preformed the NMR analysis, as well as the interpretation of the data. 
 
All spectra were acquired on a Bruker Avance III HD spectrometer operating at 599.90 MHz 
for protons, equipped with an inverse detected cryo-probe enhanced for 1H, 13C and 2H. 
The isolated compounds (Table 17) were prepared by dissolving the sample in 500 µL dimethyl 
sulfoxide (DMSO). The sample was transferred into a 5mm disposable tube. Experiments were 
typically acquired using gradient selected adiabatic versions where applicable. All experiments 
were acquired using TopSpin 3.5 pl2, at 298 K. 
 
3.8 Bioactivity testing 
 
After isolation and NMR analysis, the one compound that was possible to structure elucidate, 
compound 2, was chosen for further bioactivity testing. The dried sample was dissolved in 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, MO, USA) to create a stock solution with a 
concentration of 3.33 µg/µL. From the stock solution it was made a series of dilutions with 
concentration between 1.12-40 µM, starting with 40 µM and diluted 50:50 down to 1.12 µM. 
The sample and dilutions were stored in the refrigerator at 4 °C until the next day.  
 
3.8.1 Preparation of the test bacteria for both MIC and biofilm assays 
 
The test bacteria were stored in the same growth medium that they were cultivated, with 10% 
glycerol at -80 °C. The solution of bacteria was transferred from cryotubes while kept on ice 
to an agar plate. An inoculating loop was used to transfer a small amount from the bacterial 
stock solution to the blood agar plates. The plates were incubated at 37 C overnight and then 
stored in the fridge at 4C for two weeks. After two weeks a colony of bacteria was transferred 
to a new plate and incubated overnight for maintenance, and stored at 4 C for two weeks 






3.8.2 Antibacterial screening (MIC-assay) 
The materials and equipment used during antibacterial screening can be seen in Table 12. 
 
Table 12: Materials and equipment used in the antibacterial screening (MIC) of compound 2. 
Materials/Equipment Supplier 
Mueller Hinton broth (MH) Becton, Dickinson and Company, New Jersey, USA 
Brain heart infusion broth (BHI) Sigma-Aldrich, Missouri, USA 
Gentamycin (10 mg/mL) A2712 Merck KGaA, Germany 
Milli-Q water Millipore, Billerica, MA, USA 
Glycerol G5516 Sigma-Aldrich, Missouri, USA 
Escherichia coli ATCC® 25922 LGC Standards, UK 
Streptococcus agalactiae ATCC® 12386 LGC Standards, UK 
Blood agar plates University Hospital of North Norway (UNN) Tromsø, 
Norway 
Herasafe biological safety cabinet, Class II Thermo Fisher Scientific, Massachusetts, USA 
Incubator Unimax 1010 Heidolph Instruments GmbH & Co, Germany 
Heated Incubator MIR-262 Panasonic Healthcare, Japan 
 
 
Preparation of test bacteria 
Compound 2, the one fully structure elucidated compound, was screened for antibacterial 
effect against two bacteria, E.coli and S.agalacitae. A scoop of bacteria was transferred to 8 
mL growth media, and allowed to grow overnight at 37 °C in an incubator. 2 mL of the 
overnight cultures from the day before was transferred to 25 mL fresh cultivated medium. The 
bacteria culture was incubated for 1.5 h in an incubator at 37 °C to reach a turbidity of 0.5 
McFarland standard (1.0 x 108 bacteria/mL). After incubation, the bacterial suspensions were 
diluted 1:1000 in fresh media before being used in the antibacterial assay.  
 
Preparation of 96-well microtiter plates  
Compound 2 was dissolved in DMSO and diluted in sterile ultra-pure water to 40, 20, 10, 5, 
2.5 and 1.25 µM. 50 µL of the sample was added to two different microtiter plates (one for 
each bacterial strains) in three parallels. 50 µL of the diluted bacterial suspension was added 
to the sample (diluting the sample 1:2, giving the final test concentration half of the 
concentration previously mentioned). 50 µL growth media and 50 µL sterile ultra-pure water 
were used as negative control, while 50 µL sterile ultra-pure water and 50 µL diluted bacterial 
suspension was used as positive control. The microtiter plates were then incubated at 37 °C 





The next day the plates were checked visually for growth inhibition before measuring the 
absorbance at 600 nm. Threshold Abs600 values were used to define the compound as either 
active, questionable or inactive. 
 
The definition values used to define the compound: 
 Active  0.05 
 Questionable 0.05-0.09 
 Inactive  0.09 
 
Gentamycin control  
Gentamycin controls are performed routinely as control for normal growth of the bacteria, 
and for the assay. The controls were performed in concentrations ranging from 16 µg/mL to 
0.01 µg/mL (final test concentration), in order to determine the minimum inhibitory 
concentration (MIC) of gentamycin for the test bacteria. In a microtiter plate 50 µL of the 
gentamycin control was added to 50 µL bacterial solution, and incubated at 37 °C overnight. 
The MIC values were evaluated visually by looking for growth inhibition. Clear wells indicates 
inhibition of bacterial growth.  
 
3.8.3 Biofilm inhibiting activity screening  
The materials and equipment used during the biofilm inhibiting screening can be seen in Table 
13. 
 
Table 13: Materials and equipment used in biofilm inhibiting activity screening for compound 2. 
Materials/Equipment Supplier 
Milli-Q water Millipore, Billerica, MA, USA 
Dextrose, D9434 Sigma-Aldrich, Missouri, USA 
Ethanol 70% Sigma-Aldrich, Missouri, USA 
Tryptic soy broth (TSB), 105459 Merck KGaA, Germany 
Crystal violet, 115940 Merck KGaA, Germany 
Glucose, D9434 Sigma-Aldrich, Missouri, USA 
Staphylococcus epidermidis ATCC 35984 University Hospital of North Norway (UNN) Tromsø, 
Norway 
Staphylococcus haemolyticus Clinical isolate 8-7A, University Hospital of North 
Norway (UNN) Tromsø, Norway 
Blood agar plates University hospital (UNN) Tromsø, Norway 
Herasafe biological safety cabinet, Class II Thermo Fisher Scientific, Massachusetts, USA 
Incubator Unimax 1010 Heidolph Instruments GmbH & Co, Germany 




One scoop of each bacteria was transferred to 5 mL TSB and incubated overnight at 37 C. 
After overnight incubation, the cultures were diluted 1:100 in TSB with 1% glucose. 50 L of 
dissolved and diluted compound 2, was added to the microtiter plate in three parallels with 
concentrations as described in “3.8.2 Antibacterial screening (MIC assay)”. 50 µL of the sample 
was transferred to a microtiter plate and 50 µL S.epidermidis suspension was added to the 
sample wells. 50 µL S.epidermidis culture and 50 µL sterile ultra-pure water were used as 
positive control. 50 µL sterile ultra-pure water and 50 µL of the non-biofilm producing bacteria 
S.haemolyticus culture was used as negative control. A medium blank with TSB and 1% glucose 
was also included in the screening, with 50 µL medium and 50 µL sterile ultra-pure water. 
Then the microtiter plates were incubated overnight at 37 °C.  
 
After the overnight incubation, the plates were visually examined for growth inhibition to 
check that antibacterial activity was not misinterpreted as biofilm formation inhibiting activity. 
Clear wells indicates bacterial growth inhibition instead of inhibition of biofilm formation. The 
bacterial suspension was poured out, and the wells were rinsed with water before incubation 
for 1 h at 55 C to fixate the biofilm to the bottom of the wells. After the fixation, the biofilm 
was colored by adding 70 L 0.1 % crystal violet solution to all the wells. The colored plates 
were incubated for 5 minutes, and then the crystal violet solution was poured off and the 
plates again rinsed with water. The microtiter plates were incubated again for 1 h at 55 C for 
the plates to be completely dry. The dry plates were added 70 L 70 % ethanol to all the wells, 
and incubated for 10 minutes at room temperature before the absorbance was measured at 






4 Results  
 
4.1 UHPLC-HR-MS analysis 
All of the organic extracts of the samples M17015-M17028 (for table, see appendix A1) were 
analysed using UHPLC-HR-MS to look for novel compounds with interesting chemistry. The 
two samples that were used for further preparation and isolation, M17015 and M17017 




Figure 3: Base peak intensity chromatogram of the crude organic extract A) M17017 and B) M17015 as part of 
the dereplication run on HR-MS. Aliquots of the extract was injected onto a C18 column. The arrows with the 
compound numbers indicates each compound that was later isolated, and which peak they represent in the 
chromatogram. 
 
The Figures 4-7 show the mass spectra of the five target compounds that were nominated for 
isolation and characterization. As can be seen in Figure 4, the mass spectrum of compound 2, 
from the HR-MS (ESI orbitrap MS), the most abundant ion formed was the protonated form 
of the compound. Other ions corresponding to different adducts of the molecule can also be 








and the sodium adduct of a dimer can be seen. This increases the probability that the most 




Figure 4: Mass spectrum of compound 2, discovered in the organic extracts of M17015 and M17017. The mass 
spectra show the protonated compound and the different adducts formed in the ion source.  
 
The mass spectra for the four other target compounds, named in this thesis as compound 1, 
3, 4 and 5, are shown in Figure 5-7. All the target compounds had isotopic patterns indicative 







Figure 5: Mass spectrum of compound 5, showing the isotopic pattern of the mono-brominated 
compound found in the organic extracts of M17017 and M17015. 
 
The isotope pattern of the spectrum in Figure 5 shows two signals with similar intensity that 
are two mass units apart ( 1:1 ratio), m/z 380 and 382. There are also two signals with 
considerably lower intensity two mass units apart, m/z 381 and 383. This comes from the 
occurrence of carbon isotopes and bromine isotopes that provide an isotope pattern that is 
easily recognised when analysed by mass spectrometry. The natural abundances of carbon 
isotopes are 12C: 98.93 % and 13C: 1.07 %, Bromine isotopes are 79Br: 50.69% and 81Br: 49.31% 
(45). This indicates that this compound contain one Br in the structure. 
 
 
Table 14: Isotope patterns in relation to the different signals in the spectrum illustrated in Figure 5. 










Figure 6: Mass spectrum of the compounds 1 and 3, showing the isotopic pattern of the di-brominated 
compounds found in the organic extracts of M17017 and M17015. A) Compound 1, and B) compound 3. 
 
The MS spectrum in Figure 6 shows a pattern with three signals with a 1:2:1 ratio separated 
by two mass units, m/z 529, 531 and 533 for compound 3, and m/z 307, 309 and 311 for 
compound 1. There are also three signals with considerably lower intensity two mass units 
apart, m/z 530, 532 and 534 for compound 3, and m/z 308, 310 and 312 for compound 1, with 
the same ratio as described above. This pattern indicates that this compound contain two Br 
in the structure. The isotope pattern-signals relation for the compound in Figure 6B, is shown 
in Table 15, the same applies for the compound in Figure 6A.  
 
Table 15: Isotope patterns in relation to the different signals in the spectrum illustrated in Figure 6B. 













Figure 7: Mass spectrum of compound 4, showing the isotopic pattern of the Tri-brominated compound 
found in the organic extracts of M17017 and M17015. 
 
The MS spectrum in Figure 7 shows a pattern with four signals with a 1:3:3:1 ratio separated 
by two mass units, m/z 491, 493, 495 and 497 with high intensity signals. There are also four 
signals with considerably lower intensity two mass units apart, m/z 492, 494, 496 and 498 with 
the same ratio as described above. This pattern indicates that this compound contain three Br 
in the structure.  
 
 
Table 16: Isotope patterns in relation to the different signals in the spectrum illustrated in Figure 7. 













Table 17: Overview of the compounds, with the exact m/z, elemental composition and retention time from HR-
MS analysis. Basis of selection describes when the compounds were selected as target compounds for 
isolation. Compound 1-2 was selected after column selection for the first isolation round and compound 3-5 
was selected in the HR-MS analysis. 






1 307.928 C9H11Br2NO 1.34 Scout run 
2 197.116 C11H16O3 2.50 Scout run 
3 529.968 C17H17Br2N5O5 3.04 HR-MS  
4 491.879 C16H16Br3NO2 3.48 HR-MS  




4.2 Compound isolation 
 
Compounds 3-5 from the organic extracts of M17015 and M17017 samples were selected 
from the dereplication analysis, for isolation and purification. The M17015 sample was 
included to increase the amount of target compounds isolated from the M17017 sample. 
 
4.2.1 Preparation of the organic extract for isolation 
 
After the crude extracts of M17015 and M17017 were partitioned between hexane and 
MeOH, the resulting dried samples had reduced quantity. This is a result of removal of 






4.2.2 Column selection: Scout run 
 
Following dereplication, three compounds were selected for isolation, compound 3-5 shown 
in Table 17. In order to select the best column for compound isolation from the organic 
extract, and aid further isolation of the selected compounds, a series of scout runs were 
conducted. This entails the injection of a set volume (400 L) onto columns with different 
packing materials. The chromatography of the compound of interest, as well as co-elution of 
impurities were evaluated for each column. For the M17017 extract, the Fluoro-phenyl 
column was found to be the column that provided the best separation of the compounds of 
interest from the impurities and from each other, and that retained all of the compounds. For 
the M17015 sample, Atlantis C18 column was found to be the best column that provided the 
best separation of the compounds of interest from the impurities and from each other, and 
that retained all of the compounds. 
 
Figure 8: Base peak intensity chromatograms of the organic extract M17017, as part of a scout run. Aliquots of 
the extract were injected onto four different columns: (A) C18 Atlantis, (B) Phenyl-Hexyl, (C) Fluoro-Phenyl, (D) 











Figure 9: Base peak intensity chromatograms of the organic extract M17015, as part of a scout run. Aliquots of 
the extract were injected onto four different columns: (A) Phenyl-Hexyl, (B) Fluoro-Phenyl, (C) C18 Atlantis, (D) 
C18 Xterra. The masses of interest are the compounds called 1-5 as shown in Table 17. 
 
The results from the scout runs aided in column selection for the first round of crude 
compound isolation. In addition, the results were used to select the optimal column for further 
purification of the crudely isolated compounds from the first isolation round. After column 
selection for first round isolation of the target compounds, two other compounds (compound 
1 and 2 shown in Table 17) was also included in the study as they could easily be isolated.   
  
Compound 1 
Compound 2+3 Compound 4+5 





4.2.3 Isolation of compound 1 
 
Compound 1 was isolated from the organic extract of M17015. The compound eluted after 
6.82 minutes on the Atlantis C18 column (Figure 10A). In total 34 injections (400 µL per 
injection) were performed to inject all of the extract. The collected fractions from the first 
isolation were pooled, dried, redissolved in MeOH and injected on the C18 Xterra column to 
remove impurities co-eluting on the Atlantis C18 column (Figure 10B). In total, 0.2 mg of 
compound 1 was isolated. 
 
Figure 10: Isolation of compound 1 from the M17015 extract. (A) BPI chromatogram from the first crude 
isolation from the organic extract using Atlantis C18 column. (B) BPI chromatogram from the second isolation  
on the  Xterra C18 column, conducted to remove impurities from the crudely isolated sample. The colored areas 







4.2.4 Isolation of compound 2 
 
Compound 2 was isolated from both the organic extract of M17015 and M17017. From the 
M17015 extract the compound eluted after 8.67 minutes on the Atlantis C18 column (Figure 
11A). In total 34 injections (400 µL per injection) were performed to inject all of the extract. 
The collected fractions from the first round of isolation were pooled, dried, redissolved in 
MeOH and injected on the Xterra C18 column to remove impurities co-eluting in the Atlantis 
C18 column (Figure 11B). The collected fractions from the second isolation were then again 
pooled, dried, redissolved in MeOH and injected onto the Phenyl-Hexyl column to remove 
more impurities (Figure 11C). From the M17017 extract, the compound eluted after 7.74 
minutes on the Fluoro-Phenyl column (Figure 12A). In total 46 injections (300 µL) were 
performed to inject all of the extract. The collected fractions from the first round of isolation 
were pooled, dried, redissolved in MeOH and injected on the Phenyl-Hexyl column to remove 
impurities co-eluting in the Fluroro-Phenyl column (Figure 12B). In total, 0.2 mg of compound 
2 was isolated. 
 
Figure 11: Isolation of compound 2 from the M17015 extract. (A) BPI chromatogram from the first crude isolation 
from the organic extract using Atlantis C18 column. (B) BPI chromatogram from the second isolation  on the 
Xterra C18 column. (C) BPI chromatogram from the third isolation run on Phenyl-Hexyl column conducted to 







Figure 12: Isolation of the compound 2 from M17017 extract. (A) Base peak intensity (BPI) chromatogram from 
the first crude isolation from the organic extract using Fluoro-Phenyl column. (B) BPI chromatogram from the 
second isolation on the Phenyl-Hexyl column, conducted to remove impurities from the crudely isolated sample. 






4.2.5 Isolation of compound 3 
 
Compound 3 was isolated from both the organic extract of M17015 and M17017. From the 
M17015 extract the compound eluted after 8.42 minutes on the Atlantis C18 column (Figure 
13A). In total 34 injections (400 µL per injection) were performed to inject all of the extract. 
The collected fractions from the first round of isolation were pooled, dried, redissolved in 
MeOH and injected on the Xterra C18 column to remove impurities co-eluting in the Fluroro-
Phenyl column (Figure 13B). The collected fractions from the second isolation were then again 
pooled, dried, redissolved in MeOH and injected on the Phenyl-Hexyl column to remove more 
impurities (Figure 13C). From the M17017 extract the compound eluted after 8.08 minutes on 
the Fluoro-Phenyl column (Figure 14A). In total 46 injections (300 µL) were performed to inject 
all of the extract. The collected fractions from the first round of isolation were pooled, dried, 
redissolved in MeOH and injected on the Phenyl-Hexyl column to remove impurities co-eluting 
in the Fluroro-Phenyl column (Figure 14B). In total, 0.2 mg of compound 3 was isolated. 
 
Figure 13: Isolation of compound 3 from the M17015 extract. (A) BPI chromatogram from the first crude isolation 
from the organic extract using Atlantis C18 column. (B) BPI chromatogram from the second isolation on the Xterra 
C18 column. (C) BPI chromatogram from the third isolation on the Phenyl-Hexyl column conducted to remove 







Figure 14: Isolation of  compound 3 from the M17017 extract. (A) BPI chromatogram from the first crude isolation 
from the organic extract using Fluoro-Phenyl column. (B) BPI chromatogram from the second isolation on the 
Phenyl-Hexyl column, conducted to remove impurities from the crudely isolated sample. The colored areas 








4.2.6 Isolation of compound 4 
 
Compound 4 was isolated from the organic extract of M17015 and M17017. From the M17015 
extract, the compound eluted after 10.3 minutes on the Atlantis C18 column (Figure 15A). In 
total 34 injections (400 µL per injection) were performed to inject all of the extract. The 
collected fractions from the first round of isolation were pooled, dried, redissolved in MeOH 
and injected on the Xterra C18 column to remove impurities co-eluting on the Atlantis C18 
column (Figure 15B). The fraction from the second isolation was then again pooled, dried 
redissolved in MeOH and re-injected on the Xterra C18 column to remove more impurities 
(Figure 15C). From the M17017 extract, the compound eluted after 6.78 minutes on the 
Fluoro-Phenyl (Figure 16A). In total 46 injections (300 µL) were performed to inject all of the 
extract. The collected fractions from the first round of isolation were pooled, dried, 
redissolved in MeOH and injected on the Xterra C18 column to remove impurities co-eluting in 
the Fluroro-Phenyl column (Figure 16B). In total, 0.2 mg of compound 4 was isolated. 
 
Figure 15: Isolation of compound 4 from the M17015 extract. (A) BPI chromatogram from the first crude isolation 
from the organic extract using Atlantis C18 column. (B) BPI chromatogram from the second isolation on the Xterra 
C18 column. (C) BPI chromatogram from the third isolation run a second time on the Xterra C18 column conducted 







Figure 16: Isolation of the compound 4 from the M17017 extract. (A) Base peak intensity (BPI) chromatogram 
from the first crude isolation from the organic extract using Fluoro-Phenyl column. (B) BPI chromatogram from 
the second isolation on the Xterra C18 column, conducted to remove impurities, and to isolate compound 4 and 







4.2.7 Isolation of compound 5 
 
Compound 5 was isolated from the organic extract of M17015 and M17017. From the M17015 
extract, the compound eluted after 9.91 minutes on the Atlantis C18 column (Figure 17A). In 
total 34 injections (400 µL per injection) were performed to inject all of the extract. The 
fractions from the first round of isolation were pooled, dried, redissolved in MeOH and 
injected on the Xterra C18 column to remove impurities co eluting on the Atlantis C18 column 
(Figure 17B). The fraction from the second isolation was then again pooled, dried redissolved 
in MeOH and re-injected on the Xterra C18 column to remove more impurities (Figure 17C). 
From the M17017 extract, the compound eluted after 6.94 minutes on the Fluoro-Phenyl 
column (Figure 18A). In total 46 injections (300 µL) were performed to inject all of the extract. 
The collected fractions from the first round of isolation were pooled, dried, redissolved in 
MeOH and injected on the Xterra C18 column to remove impurities co-eluting in the Fluoro-
Phenyl column (Figure 18B). In total, 0.2 mg of compound 5 was isolated. 
 
Figure 17: Isolation of compound 5 from the M17015 extract. (A) BPI chromatogram from the first crude isolation 
from the organic extract using Atlantis C18 column. (B) BPI chromatogram from the second isolation on the Xterra 
C18 column. (C) BPI chromatogram from the third isolation run a second time on the Xterra C18 column conducted 






Figure 18: Isolation of compound 5 from the M17017 extract. (A) Base peak intensity (BPI) chromatogram from 
the first crude isolation from the organic extract using Fluoro-Phenyl column. (B) BPI chromatogram from the 
second isolation on Xterra C18 column, conducted to remove impurities, and to isolate the compound 4 and 





Table 18: Overview of the compound isolated from the organic extra and the total isolated amount of each 
compound.  












4.3 Structure elucidation 
 
All of the isolated compounds (Table 17) were analysed on NMR for structure elucidation. In 
the end only one compound was isolated in sufficient amount and purity for structure 
determination using NMR. This was compound 2 from the prep-HPLC isolation. 
 
4.3.1 NMR analysis 
Various 1D (Figures 19 and 20) and 2D (Figures 21-23) NMR experiments were used to 
determine the structure of compound 2, as shown in Figure 19-23. Compound 2 turned out to 




Figure 19: One dimensional 1H-NMR spectrum of the purified compound. The peaks are numbered 
according to the structure of compound 2 and the solvents are indicated. Chemical shift (ppm) is on the 








Figure 20: One dimensional 13C-NMR spectrum of the purified compound. The peaks are numbered 
according to the structure of compound 2. Chemical shift (ppm) is on the x-axis and peak intensity on 
the y-axis.  
 
 
Figure 21: Two-dimensional COSY spectrum of 1H, where the peaks are numbered according to the 
structure of compound 2 and the solvents are indicated. Cross peaks indicate neighbouring protons 






Figure 22: HSQC and HMBC 2D-spectrum. The peaks are numbered according to the structure of compound 2 
and the solvents are indicated. The HSQC is displayed in red and blue markings, where CH and CH3 groups are 
red and CH2 is blue. HMBC is displayed as black markings. 1H  chemical shift (ppm) is on the x-axis and 13C chemical 









Figure 23: ROESY 2D-spectrum. The peaks are numbered according to the structure of compound 2 and 
the solvents are indicated. 1H-1H correlation mediated by dipolar coupling. Determining correlation 





Figure 24: Key HMBC, COSY and ROESY correlations used to determine the structure of compound 2. 











4.4 Bioactivity screening 
 
It was only compound 2 that was selected for bioactivity screening. This compound was the 
only one that was isolated in sufficient amount and purity to determine the structure using 
NMR. The other compounds were not pure enough to determine the structure, and a very low 
amount were obtained. These compounds were therefor not selected for bioactivity 
screening.  
 
4.4.1 MIC assay 
The minimum inhibition concentration (MIC) assay is used to screen for the ability of a 
compound to inhibit growth of bacterial strains. The assay is visually inspected for growth, 
and the absorbance is measured. The absorbance is measured at 600 nm and the value reflects 
the bacterial density in each well. The known antibiotic compound gentamycin is used as a 
negative control (for normal growth of bacteria) and precision between each testing. The cut-
off absorbance value for classifying active compounds is ˂0.05.  
 
 
Figure 25: Column chart of the MIC assay run of loliolide with different concentrations. The figure illustrate the 
absorbance value measured at each concentration of loliolide with the bacteria E.coli and S.agalactiae.  
 
The column chart in figure 23 illustrate that none of the concentrations of loliolide show any 
inhibition in the growth of the two tested bacteria. Absorbance at 0.05-0.09 is classified as 




















values are over 0.09 for both bacterial strains at all concentrations, loliolide is classified as an 
inactive compound for inhibition of bacterial growth in these two bacteria.  
 
4.4.2 Biofilm inhibition assay 
The biofilm production inhibition assay screens a compounds ability to inhibit biofilm 
formation of S.epidermidis. The microtiter plate is visually inspected for inhibition of biofilm, 
and absorbance in measured. The absorbance is measured at 600 nm and the value reflects 
the density in each well. The cut-off absorbance value for classifying active compounds is 
˂0.25.  
 
Figure 26: Column chart of the biofilm production inhibition assay for loliolide at different concentrations. The 
figure illustrate the OD value measured at each concentration of loliolide with the biofilm production bacteria 
S.epidermidis.   
 
The column chart in figure 24 illustrate that none of the concentrations of loliolde show any 
inhibition of biofilm formation of the test bacteria S.epidermidis. Absorbance at 0.25-0.30 is 
classified as questionable, and absorbance above 0.30 is classified as inactive. Since all the 
absorbance values are over 0.30, loliolide is classified as an inactive compound for inhibition 
































5.1 The content of secondary metabolites in the examined hydroids 
 
As a result of the dereplication process, interesting compounds were found in all the different 
samples. A compound was determined to be interesting based on its lipophilisity, elemental 
composition and whether it is believed to be a novel compound. The HPLC chromatograms of 
all the samples, generally looked quite similar, with an intense injection peak in the beginning, 
followed by an area of less intense peaks, and several intense peaks towards the end of the 
gradient. It is the compounds eluting in the middle of the chromatogram that is interesting, 
as the compounds in the beginning is highly water soluble like sugars with low molecular 
weight, and at the end generally highly lipophilic compounds like phospholipids. Secondary 
metabolites with commercial potential to become a drug, usually have medium lipophilicity, 
and are therefore eluted in the middle of the gradient in a reversed phase HPLC system. 
Secondary metabolites may be present in abundant amount in an extract, this is however most 
often not the case. As mention earlier, the secondary metabolites are produced by the 
organism in small amounts because it is often highly potent and potentially toxic for the 
organism itself in large amounts. In addition, they are not continuously produced, and the 
secondary metabolite content will vary based on the ever-changing environment of the 
producer (46, 47). These terms may be possible reasons for the less intense signal peaks in the 
analysis. The results from the dereplication process therefor confirmed the assumption made 
when the hydroids were selected to be analyzed, that they are important source of novel 
secondary metabolites, as part of this thesis. In addition to the compounds nominated for 
isolation, it was identified several minor sample components that would be interesting to 
isolate if more sample was available.  
 
5.2 Compound isolation 
 
Dereplication 
The crude extract was first analyzed using UHPLC-HR-MS to search for novel compounds for 
isolation, structure elucidation and screening for bioactivity. The chromatogram and mass 




nominated compounds were halogenated. Primary metabolites are generally not brominated, 
and-, when brominated compounds are found in the extracts, the chances of it being a 
secondary metabolite is high. The elemental composition calculated during dereplication of a 
compound is statistically calculated based on the mass spectrum (the accurate mass and 
isotopic pattern of the compound), and is used as the first step off structure elucidation (48). 
In figures 5-7 the mass spectra are shown for all of the isolated compounds that were 
brominated. Halogenated compounds (especially bromine and chloride), have very 
characteristic isotopic patterns in the mass spectrum and are easily discovered.  This isotopic 
pattern is due to their relative atomic mass and isotopic composition (or natural abundance 
of stable isotopes).  
 
Scout run 
Before isolation, scout run analysis of the extracts were performed by injecting the extract 
onto four different columns to see how the chromatography of the target compounds were 
affected by the different column chemistries. The same gradient was used for all the columns. 
The scout run worked out well, as it was possible to use the results from this analysis when 
conducting the first, second and third round of isolation. By conducting the scout runs, one 
could see which column that gave narrow peaks and separation of the target compounds, in 
addition to impurities that eluted simultaneously. This helped decide which column was best 
to separate two compounds that eluted simultaneously and to remove impurities, to achieve 
a pure compound for further structure elucidation using NMR. In order to get a compound 
pure enough for NMR analysis, several rounds of mass guided preparative HPLC isolation, 
using columns with different packing material for each run, is most often necessary. Once a 
compound is isolated from the extract during the first round of isolation, it is concentrated 
and thus highly valuable. The scout run results enables the selecting of columns for the second 
and third isolation rounds, without having to inject the sample onto several just to see how 
the compound elute compared to sample impurities. The amount of target compounds in the 
extracts is already low, and injection of the extract as part of the scout run analysis most often 
causes significantly lower sample loss- compared to injection of a semi-pure compound in an 
attempt to identify a column and a gradient optimal to separate it from impurities co-eluting 






From the scout runs, the selection of column for the first round of purifications was based on 
the chromatography of the target compounds. In addition to the compounds selected for 
isolation based on the HR-MS analysis, two other compounds selected for isolation from the 
chosen column. Compounds that elute in the middle of the chromatogram, and appears to be 
present in abundant amount (high peak intensity) and that seems easy to isolate (the 
compound elutes in narrow peak and does not co-elute with too many impurities), will always 
be collected. This opportunistic isolation strategy has previously led to the isolation of several 
novel products at Marbio, including securidine A (49). Isolating an additional compound is not 
labor intensive, and it is better to isolate an additional compound that turns out to be 
uninteresting compared to losing a compound that could be important and have potential for 
further drug development. When doing chemistry-guided isolation, compounds with potential 
of being developed into commercially available pharmaceutical may be left out, because the 
bioactivity screening is not conducted and there is no information of potential bioactive 
compounds in the extract.  
 
5.3 Sample amount 
 
The organic extracts of M17015 and M17017 were available in low amounts, 1.10 g and 0.33 
g, respectively. This is considered to be a low sample weight, as the ideal is to have at least 6 
– 10 g of organic extract to be able to conduct bioactivity guided isolation, and around 4 - 8 g 
to conduct chemistry guided isolation. Chemistry guided isolation requires less sample 
because the need for 2 g of extract normally used for flash fractionation and bioactivity 
screening in the Marbio bioactivity screening pipeline is eliminated. As mentioned in the 
introduction, the supply of sufficient amounts of biomass is a constant problem when working 
with isolation of compounds from marine invertebrates. Marbio is co-located with Marbank, 
the Norwegian national biobank. Marbank collect samples and prepares them into organic 
extracts that can be processed further by the staff at Marbio. Over the years, several samples 
have been left unprocessed due to low weight of the collected biomass, which would result in 
low weight of their corresponding organic extracts. This would furthermore entail difficulties 
with regards to the quantities of purified compounds that can be isolated from the extracts. 




amounts of purified compounds. Because of this, many potential “high value” organisms (like 
hydroids) have been left unexamined for their content of bioactive secondary metabolites. 
 
The amount of the isolated compounds were very low from these extracts, and the weights 
of each compound were too low to be measured accurately on an analytical scale, and they 
were all measured to be approximately 0.2 mg. The amount was too low to get good signals 
on the NMR, except from compound 2, which turned out to be the known compound loliolide. 
However, the chemistry guided isolation approach used in this work has given Marbio valuable 
information for future evaluation of how to handle samples of low mass from the biobank. 
 
The wet weight of the collected samples M17015 and M17017 used for isolation in this thesis  
were 173.77 g and 63.00 g, respectively, and the total amount of each isolated compound was 
0.2 mg. To get sufficient amount of compound to determine the structure on NMR and for 
bioactivity screening, the ideally amount of pure compound would be minimum 2 mg. To 
estimate how much wet weight that should be collected to reach the minimum amount of the 
target compounds, the biomass needed is 10 times higher than already collected. Assuming 
that the amount of the target compounds was isolated from the M17015 sample only, 1.7 kg 
biomass must be collected to be able to isolate the target compound in amounts allowing its 
structure to be elucidated using NMR. 
 
The weight of loliolide accounted for 0.0001 % of the sample wet weight, which is a very low 
amount. Trabectedin (marketed as Yondelis ®) initially isolated from the Caribbean tunicate 
Ecteinascida turbinate, had a yield of 0.0001 % (50), and Ianthelline isolated from the sponge 
Stryhnus fortis yielded 0.00453 % (51). The first one represent a worst-case scenario, and the 
latter one a best-case scenario regarding compound yield from an extract. Trabectedin is 
currently marketed as antitumor chemotherapy drug for advanced soft-tissue carcinoma. The 
yield of Loliolide and the other target compounds isolated in this thesis, was approximately 
the same as Trabectedin. This proves that it is important to also focus on the compounds 
present in small amounts, even though their isolation and structure elucidation process might 
not be straight forward. The results from this thesis highlight the importance of sufficient 
sample collection. As recollection is difficult, these results might motivate heavy sampling in 




Even though it is challenging, it is possible to work further with such compounds.  
 
5.4 Compound 2: loliolide 
 
Compound 2 was the only compound isolated during this project in amounts enabling 
structure determination by various 1D and 2D-NMR experiments. From the HR-MS analysis 
shown in figure 4, the most intense ion formed was the protonated ion of compound 2, but 
other adducts were also visible, like the sodium adduct of the dimer of the compound 
(2M+Na+) which has m/z 415. During prep-HPLC-MS isolation, compound 2 gave a signal at 
m/z 415, this means that the ion formed in prep-HPLC-MS was the sodium adduct of the 
dimer. The mass range in the prep-HPLC-MS isolation was set to start at m/z 200 and end at 
m/z 1000, so the mass of the protonated compound was too low to be detected, and one was 
fooled into thinking the compound had a higher mass than it actually had. Compound 2 was 
not selected during dereplication, and the isolated ion with m/z 415 was not found in the 
previously run HR-MS analysis (dereplication). The purified isolated compound was run on 
another HR-MS instrument to find the elemental composition to help determining the 
structure by NMR analysis. If the purified compound had been dereplicated at an earlier stage, 
one might have found that the compound was the previously known loliolide from the 
databases used for searching after known compounds.  
 
The mass of compound 2 is 196.116, which is significantly lower compared to the other 
compounds isolated as part of this thesis. This means that the numbers of moles in the sample 
was higher than for the other compounds that were isolated, even though the weight was 
approximately the same. The higher number of moles of compound 2 relative to the other 
isolated compounds and higher purity can be reasons why compound 2 was the only one that 






5.5 Microorganisms associated with the collected macroorganisms 
 
Most of the compounds that are isolated from collected samples of marine invertebrates 
currently on the marked as a drug or in different phases of clinical trials, are produced or 
predicted to be produced by microorganisms (especially bacteria) living in symbiosis with the 
invertebrates (52). In many cases, the bacteria are often specific one, or a selected few host, 
and are dependent of the host to survive. It therefor makes sense that the bacteria are 
producing secondary metabolites that insures the survival of its invertebrate host. To access 
these compounds, it is often needed to collect the invertebrate hosts. Most bacteria cannot 
be cultured in the lab, and recreating the environment in which the bacteria produces the 
desired secondary metabolites is also challenging (8, 9). Loliolide has been isolated from 
several sources, both terrestrial and marine (53). These varying sources can indicate that 
microorganisms produce the compound. It can be that same microorganism lives in symbiosis 
with both terrestrial and marine organisms. However, it may be more likely that the producer 




5.6 Bioactivity screening 
 
The Loliolide was screened for bioactivity in two different bioassays, one antibacterial 
screening (MIC assay) testing on two different bacteria, one gram positive (S.agalactiae) and 
one gram negative (E.coli). The other was an anti-biofilm inhibiting activity screening using the 
biofilm producing bacteria S.epidermidis. No activity was found in any of the screenings. 
Loliolide was for the first time isolated from the English Ryegrass Lolium perenne in 1964, the 
structure was elucidated and named after the English Rye grass (54). After this discovery, 
loliolide has been identified in queens of the red ant Solenopsis invictra in 1983 and in the 








Five compounds were isolated from the organic extracts of hydroids using the chemistry-
guided isolation approach. After isolation, one compound was pure enough and isolated in 
sufficient amount to allow structure elucidation using NMR analysis. This compound turned 
out to be the previously reported compound Loliolide. Loliolide was screened for antibacterial 
activity and anti-biofilm formation activity, but did not display any bioactivity at the 
concentration screened in the bioassays. 
 
The results in this thesis demonstrate: 
 
 The potential of hydroids as basis for secondary metabolite isolation and the 
challenges regarding the supply of sufficient hydroid biomass to allow isolation of the 
compounds in amounts sufficient for structure elucidation and bioactivity evaluation 
 The importance of using dereplication to nominate compounds for isolation from 
complex samples such as crude extracts, based on compound novelty 
 How amount of collected biomass is crucial for the success of chemistry-guided 
isolation, but also that chemistry-guided isolation requires less biomass compared to 
bioactivity-guided isolation and thus is a valid approach when isolating compounds 
from samples where large amount of biomass is difficult to collect, as is the case when 
collecting hydroids 
 That bioprospecting of collected marine hydroids enables discovery of novel 
halogenated secondary metabolites, as well as previously reported compounds from 
other species 
 Further work: aim to collect the minimum amounts of biomass suggested by the result 
of this project (1.7 kg) of herein analysed hydroids to enable isolation of target 
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A1: Overview of all the samples of the different family, genus and species of Hydroids collected 
and stored at Marbio. All samples were analyzed using UHPLC-HR-MS to search for novel 
compounds, but due to the weight of the extracts only the M17015 and M17017 samples were 
used as part of this project. 
 
Table 19: Overview over the samples of the different family of hydroids examined as part of  
 this thesis. 
 





M17015 Mix of different families   173.77 g 1.1 g 
M17016 SERTULARIIDAE ABIETINARIA ABIETINA 142 g 1.0 g 
M17017 LAFOEIDAE GRAMMARIA ABIETINA 64 g 0.33 g 
M17018 SERTULARIIDAE ABIETINARIA ABIETINA 55 g 0.28 g 
M17019 SERTULARIIDAE SYMPLECTOSCYPHUS TRICUSPIDATUS 40 g 0.13 g 
M17020 HALECIIDAE HALECIUM MURICATUM 55 g 0.29 g 
M17021 SERTULARIIDAE SERTULARIA MIRABILIS 15.32 g 0.05 g 
M17022 LAFOEIDAE GRAMMARIA ABIETINA 18.64 g 0.04 g 
M17023 SERTULARIIDAE ABIETINARIA ABIETINA 21 g 0.09 g 
M17024 SERTULARIIDAE THUIARIA SP I 18.07 g 0.11 g 
M17025 HALECIIDAE HALECIUM LABROSUM 21.82 g 0.13 g 
M17026 LAFOEIDAE LAFOEA DUMOSA 9 g 0.16 g 
M17027 CAMPANULARIIDAE RHIZOCAULUS VERTICILLATUS 13 g 0.14 g 
M17028 SERTULARIIDAE ABIETINARIA FILICULA 4 g 0.2x 10-6 g 
